Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option
GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the […]
News
Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million
GOTHENBURG, Sweden, May 25, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the
Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million
GOTHENBURG, Sweden, May 18, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the
Isofol completes recruitment of Japanese patients in the global phase III AGENT study
GOTHENBURG, Sweden, May 6, 2021 – In December 2020, Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market:
Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million
GOTHENBURG, Sweden, April 28, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), hereby announces that
Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that
Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announced on
Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients
GOTHENBURG, Sweden, March 19, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that
Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study
GOTHENBURG, Sweden, January 15, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that
Isofol reaches 440 patients in global Phase III AGENT study
GOTHENBURG, Sweden, December 9, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that